Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.54
NAS:BIIB's Cash-to-Debt is ranked lower than
89% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:BIIB: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 2.83 Max: No Debt
Current: 0.54
Equity-to-Asset 0.56
NAS:BIIB's Equity-to-Asset is ranked lower than
64% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:BIIB: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.77 Max: 0.96
Current: 0.56
0.48
0.96
Debt-to-Equity 0.51
NAS:BIIB's Debt-to-Equity is ranked lower than
69% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:BIIB: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:BIIB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 0.78
Current: 0.51
0.01
0.78
Debt-to-EBITDA 1.09
NAS:BIIB's Debt-to-EBITDA is ranked higher than
67% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:BIIB: 1.09 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:BIIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13  Med: 0.64 Max: 1.2
Current: 1.09
0.13
1.2
Interest Coverage 18.79
NAS:BIIB's Interest Coverage is ranked lower than
80% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BIIB: 18.79 )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 18.79  Med: 42.88 Max: 134.66
Current: 18.79
18.79
134.66
Piotroski F-Score: 5
Altman Z-Score: 6.24
Beneish M-Score: -2.66
WACC vs ROIC
5.05%
24.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 40.25
NAS:BIIB's Operating Margin % is ranked higher than
95% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:BIIB: 40.25 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 24.59  Med: 33.48 Max: 45.44
Current: 40.25
24.59
45.44
Net Margin % 29.44
NAS:BIIB's Net Margin % is ranked higher than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:BIIB: 29.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 29.44
19.11
32.95
ROE % 28.96
NAS:BIIB's ROE % is ranked higher than
96% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:BIIB: 28.96 )
Ranked among companies with meaningful ROE % only.
NAS:BIIB' s ROE % Range Over the Past 10 Years
Min: 10.06  Med: 20.75 Max: 35.15
Current: 28.96
10.06
35.15
ROA % 15.70
NAS:BIIB's ROA % is ranked higher than
95% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:BIIB: 15.70 )
Ranked among companies with meaningful ROA % only.
NAS:BIIB' s ROA % Range Over the Past 10 Years
Min: 7.43  Med: 14.4 Max: 22.42
Current: 15.7
7.43
22.42
ROC (Joel Greenblatt) % 125.84
NAS:BIIB's ROC (Joel Greenblatt) % is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:BIIB: 125.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.17  Med: 90.54 Max: 189.7
Current: 125.84
54.17
189.7
3-Year Revenue Growth Rate 21.60
NAS:BIIB's 3-Year Revenue Growth Rate is ranked higher than
75% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:BIIB: 21.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.1  Med: 21.6 Max: 78.2
Current: 21.6
-15.1
78.2
3-Year EBITDA Growth Rate 28.10
NAS:BIIB's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:BIIB: 28.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 28.1
0
127.9
3-Year EPS without NRI Growth Rate 29.40
NAS:BIIB's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:BIIB: 29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66  Med: 34.9 Max: 205.2
Current: 29.4
-66
205.2
GuruFocus has detected 3 Warning Signs with Biogen Inc NAS:BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BIIB's 30-Y Financials

Financials (Next Earnings Date: 2018-01-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BIIB Guru Trades in Q4 2016

John Hussman 350 sh (New)
John Burbank 5,904 sh (New)
Eric Mindich 327,882 sh (+412.32%)
David Dreman 602 sh (+301.33%)
Jim Simons 707,495 sh (+196.94%)
Jeff Auxier 25,305 sh (+11.80%)
Lee Ainslie 10,880 sh (+4.82%)
Vanguard Health Care Fund 3,841,803 sh (+2.18%)
John Buckingham 16,934 sh (+1.75%)
Ken Fisher 101,887 sh (+1.16%)
Ron Baron 6,625 sh (+0.73%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Eric Mindich 400,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (unchged)
George Soros Sold Out
Richard Pzena Sold Out
Sarah Ketterer Sold Out
Pioneer Investments Sold Out
Ray Dalio Sold Out
PRIMECAP Management 15,584,387 sh (-0.70%)
Ronald Muhlenkamp 23,279 sh (-0.85%)
Mario Gabelli 1,872 sh (-1.32%)
Joel Greenblatt 240,311 sh (-2.10%)
Richard Snow 192,361 sh (-5.49%)
HOTCHKIS & WILEY 286,800 sh (-6.31%)
Frank Sands 2,578,909 sh (-7.54%)
Andreas Halvorsen 1,918,812 sh (-12.24%)
Murray Stahl 6,655 sh (-13.63%)
First Eagle Investment 257,025 sh (-43.79%)
Steven Cohen 53,542 sh (-54.45%)
John Paulson 52,200 sh (-83.05%)
Paul Tudor Jones 7,815 sh (-93.78%)
» More
Q1 2017

BIIB Guru Trades in Q1 2017

Leucadia National 1,716 sh (New)
Richard Pzena 759 sh (New)
Jeremy Grantham 1,480 sh (New)
Manning & Napier Advisors, Inc 122,675 sh (New)
Caxton Associates 1,200 sh (New)
Pioneer Investments 54,344 sh (New)
Ray Dalio 45,447 sh (New)
Steven Cohen 216,470 sh (+304.30%)
Jim Simons 848,961 sh (+20.00%)
Joel Greenblatt 275,460 sh (+14.63%)
Ronald Muhlenkamp 25,557 sh (+9.79%)
Ken Fisher 109,414 sh (+7.39%)
Jeff Auxier 25,875 sh (+2.25%)
John Buckingham 17,061 sh (+0.75%)
Vanguard Health Care Fund 3,841,803 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Ron Baron 6,625 sh (unchged)
First Eagle Investment 1,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
David Dreman Sold Out
First Eagle Investment Sold Out
HOTCHKIS & WILEY 286,572 sh (-0.08%)
PRIMECAP Management 15,477,424 sh (-0.69%)
Richard Snow 186,104 sh (-3.25%)
John Burbank 5,671 sh (-3.95%)
Frank Sands 2,475,937 sh (-3.99%)
Mario Gabelli 1,772 sh (-5.34%)
Lee Ainslie 9,610 sh (-11.67%)
John Hussman 250 sh (-28.57%)
Murray Stahl 4,645 sh (-30.20%)
Andreas Halvorsen 688,765 sh (-64.10%)
Eric Mindich 111,191 sh (-66.09%)
John Paulson 17,300 sh (-66.86%)
Paul Tudor Jones 1,752 sh (-77.58%)
Eaton Vance Worldwide Health Sciences Fund 154,569 sh (-7.17%)
» More
Q2 2017

BIIB Guru Trades in Q2 2017

David Dreman 3,705 sh (New)
John Hussman 10,000 sh (+3900.00%)
Jeremy Grantham 24,484 sh (+1554.32%)
Manning & Napier Advisors, Inc 814,369 sh (+563.84%)
Steven Cohen 892,101 sh (+312.11%)
Ron Baron 12,935 sh (+95.25%)
Lee Ainslie 15,230 sh (+58.48%)
Caxton Associates 1,500 sh (+25.00%)
Richard Snow 215,182 sh (+15.62%)
Jeff Auxier 28,170 sh (+8.87%)
Mairs and Power 1,053 sh (+2.73%)
HOTCHKIS & WILEY 286,572 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
Murray Stahl 4,645 sh (unchged)
Richard Pzena Sold Out
Leucadia National Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
John Paulson Sold Out
John Buckingham 17,055 sh (-0.04%)
Ronald Muhlenkamp 25,545 sh (-0.05%)
Ken Fisher 109,129 sh (-0.26%)
PRIMECAP Management 15,391,401 sh (-0.56%)
Ray Dalio 44,981 sh (-1.03%)
Mario Gabelli 1,750 sh (-1.24%)
Vanguard Health Care Fund 3,784,603 sh (-1.49%)
Jim Simons 762,861 sh (-10.14%)
Joel Greenblatt 162,464 sh (-41.02%)
Frank Sands 1,278,163 sh (-48.38%)
Pioneer Investments 26,290 sh (-51.62%)
Eaton Vance Worldwide Health Sciences Fund 132,800 sh (-14.08%)
» More
Q3 2017

BIIB Guru Trades in Q3 2017

David Carlson 95,000 sh (New)
Stanley Druckenmiller 48,000 sh (New)
Pioneer Investments 46,690 sh (+77.60%)
Ron Baron 12,951 sh (+0.12%)
John Buckingham 17,073 sh (+0.11%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,053 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
John Hussman Sold Out
Lee Ainslie Sold Out
Caxton Associates Sold Out
Jeff Auxier 28,145 sh (-0.09%)
Ken Fisher 107,864 sh (-1.16%)
PRIMECAP Management 15,212,914 sh (-1.16%)
Ray Dalio 44,198 sh (-1.74%)
Vanguard Health Care Fund 3,712,503 sh (-1.91%)
Richard Snow 210,459 sh (-2.19%)
Ronald Muhlenkamp 24,547 sh (-3.91%)
HOTCHKIS & WILEY 274,772 sh (-4.12%)
Mario Gabelli 1,675 sh (-4.29%)
Frank Sands 1,207,172 sh (-5.55%)
Manning & Napier Advisors, Inc 737,735 sh (-9.41%)
Steven Cohen 507,922 sh (-43.06%)
Joel Greenblatt 63,039 sh (-61.20%)
Jim Simons 120,161 sh (-84.25%)
Jeremy Grantham 1,480 sh (-93.96%)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (-11.72%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -1.91%0.04%$271.76 - $329.69 $ 309.065%3,712,503
HOTCHKIS & WILEY 2017-09-30 Reduce -4.12%0.01%$271.76 - $329.69 $ 309.065%274,772
Ken Fisher 2017-09-30 Reduce -1.16%$271.76 - $329.69 $ 309.065%107,864
Joel Greenblatt 2017-09-30 Reduce -61.20%0.38%$271.76 - $329.69 $ 309.065%63,039
Ronald Muhlenkamp 2017-09-30 Reduce -3.91%0.08%$271.76 - $329.69 $ 309.065%24,547
Ron Baron 2017-09-30 Add 0.12%$271.76 - $329.69 $ 309.065%12,951
Mario Gabelli 2017-09-30 Reduce -4.29%$271.76 - $329.69 $ 309.065%1,675
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.03%$246.54 - $286.89 $ 309.0617%3,784,603
Joel Greenblatt 2017-06-30 Reduce -41.02%0.39%$246.54 - $286.89 $ 309.0617%162,464
Ken Fisher 2017-06-30 Reduce -0.26%$246.54 - $286.89 $ 309.0617%109,129
Ronald Muhlenkamp 2017-06-30 Reduce -0.05%$246.54 - $286.89 $ 309.0617%25,545
Ron Baron 2017-06-30 Add 95.25%0.01%$246.54 - $286.89 $ 309.0617%12,935
David Dreman 2017-06-30 New Buy0.55%$246.54 - $286.89 $ 309.0617%3,705
Mario Gabelli 2017-06-30 Reduce -1.24%$246.54 - $286.89 $ 309.0617%1,750
John Paulson 2017-06-30 Sold Out 0.06%$246.54 - $286.89 $ 309.0617%0
Richard Pzena 2017-06-30 Sold Out $246.54 - $286.89 $ 309.0617%0
Leucadia National 2017-06-30 Sold Out 0.04%$246.54 - $286.89 $ 309.0617%0
HOTCHKIS & WILEY 2017-03-31 Reduce -0.08%$251.68 - $297.85 $ 309.0612%286,572
Joel Greenblatt 2017-03-31 Add 14.63%0.12%$251.68 - $297.85 $ 309.0612%275,460
Ken Fisher 2017-03-31 Add 7.39%$251.68 - $297.85 $ 309.0612%109,414
Ronald Muhlenkamp 2017-03-31 Add 9.79%0.19%$251.68 - $297.85 $ 309.0612%25,557
John Paulson 2017-03-31 Reduce -66.86%0.11%$251.68 - $297.85 $ 309.0612%17,300
Mario Gabelli 2017-03-31 Reduce -5.34%$251.68 - $297.85 $ 309.0612%1,772
Leucadia National 2017-03-31 New Buy0.04%$251.68 - $297.85 $ 309.0612%1,716
Richard Pzena 2017-03-31 New Buy$251.68 - $297.85 $ 309.0612%759
David Dreman 2017-03-31 Sold Out 0.09%$251.68 - $297.85 $ 309.0612%0
First Eagle Investment 2017-03-31 Sold Out 0.17%$251.68 - $297.85 $ 309.0612%0
Vanguard Health Care Fund 2016-12-31 Add 2.18%0.06%$251.83 - $298.71 $ 309.0613%3,841,803
HOTCHKIS & WILEY 2016-12-31 Reduce -6.31%0.03%$251.91 - $298.81 $ 309.0613%286,800
First Eagle Investment 2016-12-31 Reduce -43.79%0.16%$251.91 - $298.81 $ 309.0613%257,025
Joel Greenblatt 2016-12-31 Reduce -2.10%0.02%$251.91 - $298.81 $ 309.0613%240,311
Ken Fisher 2016-12-31 Add 1.16%$251.83 - $298.71 $ 309.0613%101,887
John Paulson 2016-12-31 Reduce -83.05%0.88%$251.91 - $298.81 $ 309.0613%52,200
Ronald Muhlenkamp 2016-12-31 Reduce -0.85%0.02%$251.91 - $298.81 $ 309.0613%23,279
Ron Baron 2016-12-31 Add 0.73%$251.91 - $298.81 $ 309.0613%6,625
Mario Gabelli 2016-12-31 Reduce -1.32%$251.91 - $298.81 $ 309.0613%1,872
David Dreman 2016-12-31 Add 301.33%0.07%$251.91 - $298.81 $ 309.0613%602
Richard Pzena 2016-12-31 Sold Out $251.91 - $298.81 $ 309.0613%0
George Soros 2016-12-31 Sold Out 0.02%$251.91 - $298.81 $ 309.0613%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, ASX:CSL, NAS:REGN, LSE:SHP, NAS:VRTX, XSWX:ATLN, NAS:GILD, NAS:ALXN, NAS:INCY, XKRX:207940, XKRX:068270, XMCE:GRF.P, OCSE:NZYM B, SZSE:002252, NAS:BMRN, XBRU:UCB, OCSE:GEN, NAS:ALNY, NAS:KITE, NAS:SGEN » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and is launching Spinraza with partner Ionis.

Top Ranked Articles about Biogen Inc

The Curious Career of Steven Cohen Cohen has been spectacularly successful as an investor, but his image was tainted by an insider trading scandal. Additionally, his returns may not be as robust as the numbers suggest
Few investment gurus have as controversial a record as Steven Cohen (Trades, Portfolio). He has won acclaim for outstanding returns over the long term, he’s been cursed for the way he does business by other Wall Streeters and he was at the center of an insider trading scandal, one that saw several of his traders convicted. Read more...
Research Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
Wall Street on the Bullish Path Biogen rises on upgrade
U.S. stock market indexes opened in green on Thursday. The S&P 500, the Nasdaq and the Dow Jones are ready for another session of records highs, with investors awaiting several speeches by Federal Reserve officials. Further, the dollar index is near a two-month high of 93.83. Read more...
AbbVie's Venclexta Achieves Primary Endpoint The treatment prolonged progression-free survival in leukemia patients
AbbVie Inc. (NYSE:ABBV) announced Sept. 18 the phase 3 Murano trial achieved its primary endpoint. Read more...
Steven Cohen Dives Into Array BioPharma Guru keeps adding to positions in health care industry
On Sept. 11, Point72 manager Steven Cohen (Trades, Portfolio) invested in 6,766,507 shares of Array BioPharma Inc. (NASDAQ:ARRY), according to GuruFocus real-time picks. With this transaction, the guru increased his position 281.23%. Read more...
David Dreman’s Top 5 Health Care Buys for the 2nd Quarter Guru takes new positions in stocks he previously sold
Dreman Value Management founder David Dreman (Trades, Portfolio) established 210 new positions in the second quarter, of which 20 were in health care companies. His top five health care buys were Aetna Inc. (NYSE:AET), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB) and Cardinal Health Inc. (NYSE:CAH). Read more...
Steven Cohen Plunges Into Opioid Replacement Maker Pacira Point72 bolsters position more than a thousand percent
Steven Cohen (Trades, Portfolio), founder of Point72 Asset Management, made a 1098% increase to his holding of Pacira Pharmaceuticals (NASDAQ:PCRX), he revealed this week. Read more...
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies

Ratios

vs
industry
vs
history
PE Ratio 18.93
BIIB's PE Ratio is ranked higher than
65% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. BIIB: 18.93 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 20.7 Max: 76.25
Current: 18.93
10.8
76.25
Forward PE Ratio 13.11
BIIB's Forward PE Ratio is ranked higher than
74% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. BIIB: 13.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.93
BIIB's PE Ratio without NRI is ranked higher than
67% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. BIIB: 18.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 20.7 Max: 77.48
Current: 18.93
10.8
77.48
Price-to-Owner-Earnings 22.19
BIIB's Price-to-Owner-Earnings is ranked higher than
61% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. BIIB: 22.19 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.96  Med: 22.14 Max: 154.47
Current: 22.19
9.96
154.47
PB Ratio 5.08
BIIB's PB Ratio is ranked lower than
64% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIIB: 5.08 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.48 Max: 8.84
Current: 5.08
1.71
8.84
PS Ratio 5.59
BIIB's PS Ratio is ranked higher than
68% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. BIIB: 5.59 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.34 Max: 10.99
Current: 5.59
2.58
10.99
Price-to-Free-Cash-Flow 24.41
BIIB's Price-to-Free-Cash-Flow is ranked higher than
53% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. BIIB: 24.41 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 19.24 Max: 36.13
Current: 24.41
9.25
36.13
Price-to-Operating-Cash-Flow 14.52
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. BIIB: 14.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.67 Max: 32.48
Current: 14.52
7.22
32.48
EV-to-EBIT 14.18
BIIB's EV-to-EBIT is ranked higher than
64% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. BIIB: 14.18 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14.4 Max: 31.8
Current: 14.18
7.5
31.8
EV-to-EBITDA 11.41
BIIB's EV-to-EBITDA is ranked higher than
69% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. BIIB: 11.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.8 Max: 24.8
Current: 11.41
6.1
24.8
EV-to-Revenue 5.77
BIIB's EV-to-Revenue is ranked higher than
69% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. BIIB: 5.77 )
Ranked among companies with meaningful EV-to-Revenue only.
BIIB' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 5.3 Max: 10.9
Current: 5.77
2.5
10.9
PEG Ratio 0.65
BIIB's PEG Ratio is ranked higher than
80% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. BIIB: 0.65 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.75 Max: 35.41
Current: 0.65
0.31
35.41
Shiller PE Ratio 33.55
BIIB's Shiller PE Ratio is ranked higher than
63% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. BIIB: 33.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.31  Med: 75.9 Max: 686.29
Current: 33.55
29.31
686.29
Current Ratio 2.19
BIIB's Current Ratio is ranked lower than
72% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BIIB: 2.19 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.16 Max: 20.41
Current: 2.19
0.78
20.41
Quick Ratio 1.90
BIIB's Quick Ratio is ranked lower than
73% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. BIIB: 1.90 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.88 Max: 20.41
Current: 1.9
0.7
20.41
Days Inventory 237.44
BIIB's Days Inventory is ranked lower than
76% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. BIIB: 237.44 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 237.44
219.47
266.3
Days Sales Outstanding 48.33
BIIB's Days Sales Outstanding is ranked higher than
63% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. BIIB: 48.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 45.32 Max: 48.62
Current: 48.33
39.79
48.62
Days Payable 72.72
BIIB's Days Payable is ranked higher than
63% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. BIIB: 72.72 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 69.07  Med: 98.14 Max: 148.21
Current: 72.72
69.07
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BIIB: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: -0.3 Max: 30.9
Current: 3
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.87
BIIB's Price-to-Tangible-Book is ranked lower than
88% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. BIIB: 13.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.07  Med: 4.89 Max: 24.42
Current: 13.87
0.07
24.42
Price-to-Intrinsic-Value-Projected-FCF 1.66
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. BIIB: 1.66 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.65 Max: 12.97
Current: 1.66
0.05
12.97
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.66
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 27 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. BIIB: 0.66 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BIIB' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 0.63 Max: 0.99
Current: 0.66
0.46
0.99
Price-to-Median-PS-Value 1.05
BIIB's Price-to-Median-PS-Value is ranked lower than
57% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BIIB: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.94 Max: 13.39
Current: 1.05
0.05
13.39
Price-to-Peter-Lynch-Fair-Value 0.76
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
86% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. BIIB: 0.76 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.14 Max: 18.88
Current: 0.76
0.41
18.88
Price-to-Graham-Number 3.42
BIIB's Price-to-Graham-Number is ranked lower than
68% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. BIIB: 3.42 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.07  Med: 2.83 Max: 33.65
Current: 3.42
0.07
33.65
Earnings Yield (Greenblatt) % 7.05
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. BIIB: 7.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 13.4
Current: 7.05
3.1
13.4
Forward Rate of Return (Yacktman) % 31.38
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
82% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. BIIB: 31.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.5  Med: 30.2 Max: 45.7
Current: 31.38
0.5
45.7

More Statistics

Revenue (TTM) (Mil) $11,838.90
EPS (TTM) $ 16.33
Beta0.48
Short Percentage of Float1.21%
52-Week Range $244.28 - 348.84
Shares Outstanding (Mil)211.48

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 11,996 12,316 12,630 13,263
EPS ($) 21.56 23.18 23.27 25.48
EPS without NRI ($) 21.56 23.18 23.27 25.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.57%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}